Domperidone + paracetamol


Concise Prescribing Info
Indications/Uses
Migraine.
Dosage/Direction for Use
Adult: PO Per tab contains domperidone 10 mg and paracetamol 500 mg: 2 tab at the onset of attack, may repeat 4 hrly if needed. Max: 4 g paracetamol/day.
Contraindications
Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone or chronic admin or for prophylaxis of postoperative nausea and vomiting.
Special Precautions
Phaeochromocytoma; children, elderly; renal or hepatic impairment, risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy, lactation and alcohol-dependent patients.
Adverse Reactions
Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, nausea, allergic reactions, skin rashes, acute renal tubular necrosis.
Potentially Fatal: Domperidone: convulsions, arrhythmias and cardiac arrest, dysrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures, hypertensive crisis in patients with pheochromocytoma are seen.
Paracetamol, very rare, blood dyscrasias (eg, thrombocytopaenia, leucopaenia, neutropaenia, agranulocytosis); liver damage are seen.
Drug Interactions
Domperidone reduces absorption of oral digoxin, increases absorption of aspirin and oral diazepam. Enhances CNS depression by phenothiazines. Antimuscarinic agents and opioids antagonise GI effects of domperidone.
Paracetamol reduced absorption of cholestyramine within 1 hr of admin and accelerates absorption of metoclopramide.
ATC Classification
A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
N02BE01 - paracetamol ; Belongs to the class of anilide preparations. Used to relieve pain and fever.
Disclaimer: This information is independently developed by CIMS based on domperidone + paracetamol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in